Kinevant Sciences
Research - New York, New York, United States
Kinevant Sciences Employees
Kinevant Sciences Senior Management
Kinevant Sciences Details
Kinevant Sciences is a clinical-stage biopharmaceutical company dedicated to treating rare autoimmune diseases with significant unmet need. Our lead candidate, namilumab, is an investigational monoclonal antibody being developed for the treatment of sarcoidosis. Namilumab targets GM-CSF, a key pro-inflammatory cytokine and growth factor implicating in the pathogenesis of sarcoidosis and other inflammatory disorders. We plan to initiate a global Phase 2 clinical trial in the first half of 2022 investigating namilumab in pulmonary sarcoidosis, which affects ~90% of all sarcoidosis patients.
Kinevant Sciences Technologies
Email Providers
Outlook
Domain Name Services
Dyn Managed DNS
Other
Microsoft Office 365
Hosting
Google Cloud Hosting
Recruitment
Greenhouse.io